目前,随着大量的新药涌入临床,出现了一些原输液配伍禁忌表中没有列出的新药配伍禁忌,在临床应用中,我们通过观察和积累,发现注射用甲磺酸帕珠沙星与泮托拉唑之间存在配伍禁忌,需引起重视。2012年3月,笔者在使用注射用甲磺酸帕珠沙星(商品名莱美净)与注射用泮托拉唑(商品名韦迪)连续静脉输入时,输液管中呈现淡橘黄色。我们立即停止输液,更换输液管并观察病情变化,患者未发生输液反应。对此现象我们进行了实验观察,按照临床实际应用配置方法,将注射用甲磺酸帕珠沙星(商品名莱美净)0.3g溶于100ml生理盐水,缓慢滴入注射用泮托拉唑(商品名韦迪)40mg溶于100ml生理盐水溶液中,输液管中液体出现淡橘黄色,静置5～6min,液体变成深 At present, with the influx of a large number of new drugs into the clinic, some contraindications to incompatibility of new drugs, which are not listed in the original taboo compatibility tabulation, have emerged. In clinical application, we found that pazufloxacin mesylate Pantoprazole incompatibility exists between the need to pay attention. In March 2012, the author showed a pale orange color in the infusion tube when a continuous intravenous infusion of pazufloxacin mesylate (brand name rameseptam) and pantoprazole for injection (brand name vide) was used. We immediately stop the infusion, replace the infusion tube and observe the changes in the condition, the patient did not respond to infusion. We observed the phenomenon of this experiment, in accordance with the actual application of clinical configuration method, the injection of pazufloxacin mesylate (brand name Lemec net) 0.3g dissolved in 100ml of saline, was slowly dropped into the injection of pantoprazole (Trade name Vedi) 40mg dissolved in 100ml saline solution, infusion tube pale yellow orange liquid, stand for 5 ~ 6min, the liquid becomes deep